AI Summary
✦ ClarthaValuation Metrics
Trading 51.5% above historical median. Valuation is declining — currently in the strongly overvalued zone (z-score: +1.43). Confidence: 73%.
Live forward EPS implies next-12-month EPS of ₹13.50. Applying the stock's normalized valuation corridor produces a fair range of ₹240.57 to ₹363.15, with base value near ₹271.75 (-2.6% vs current price).
Live forward estimate anchored to the company's historical valuation corridor.
Forward EPS
₹13.50
Forward P/E
20.7x
Base Fair Value
₹271.75
Fair Range
₹240.57 - ₹363.15
Upside To Base
-2.6%
Estimate Source
Live forward EPS
Growth Estimate
+63.4%
5Y Average
16.25
Current
30.49
Overvalued
26.90
Undervalued
17.82
5Y Average
11.03
Current
20.69
Overvalued
15.73
Undervalued
4.79
5Y Average
2.28
Current
4.28
Overvalued
3.26
Undervalued
0.99
Peers & Comparison
Sector: Health Care · Theme: Pharmaceuticals
| Company | Rev. Growth | Margin | P/E | vs Avg | 52W Perf. |
|---|---|---|---|---|---|
CAPLIN POINT LAB LTD. CAPLIPOINTPharmaceuticals | +19.0% | 29.3% | 31.2x Undervalued | -32% vs avg | +22.8% |
ALIVUS LIFE SCIENCES LTD ALIVUSPharmaceuticals | +6.4% | 23.3% | 27.5x Undervalued | -40% vs avg | +43.2% |
AKUMS DRUGS AND PHARMA L AKUMSPharmaceuticals | +9.6% | 5.9% | 43.6x Fair | -5% vs avg | +51.8% |
BLUE JET HEALTHCARE LTD BLUEJETPharmaceuticals | -17.4% | 26.5% | 43.6x Fair | -5% vs avg | -25.8% |
ABBOTT INDIA LIMITED ABBOTINDIAPharmaceuticals | +6.5% | 22.4% | 38.8x Undervalued | -16% vs avg | -15.4% |
IPCA LABORATORIES LTD IPCALABPharmaceuticals | +6.3% | 11.8% | 38.8x Undervalued | -16% vs avg | +22.5% |
AJANTA PHARMA LIMITED AJANTPHARMPharmaceuticals | +24.8% | 19.6% | 38.5x Undervalued | -16% vs avg | +30.0% |
ASTRAZENECA PHARMA IND LT ASTRAZENPharmaceuticals | +20.4% | 8.2% | 106.8x Premium | +132% vs avg | -6.7% |
MARKSANS PHARMA LIMITED trades at a discount (30.5x vs peer avg 46.1x), suggesting potential undervaluation relative to the Pharmaceuticals cohort. Peers include CAPLIN POINT LAB LTD., ALIVUS LIFE SCIENCES LTD, AKUMS DRUGS AND PHARMA L — selected based on business model, industry classification, market cap similarity, and business theme alignment.
Financials
Real statement data for revenue, earnings quality, conversion, and balance-sheet coverage. Monetary values are shown in Rs crore.
Latest revenue
₹362 CrMar 2026Latest net profit
₹92 CrMar 2026Latest EPS
₹2.03Mar 2026Net margin
29.0%Mar 2026Performance
Bars show revenue and net profit. The line shows net margin.
- Revenue
- Net income
- Net margin %
Earnings
Revenue is shown in crores. EPS is rupees per share.
- Revenue
- EPS
Revenue to profit conversion
Bridge from operating numbers to profit for the latest reported period.
Latest reported period: Mar 2026
Debt level and coverage
Debt, cash and free cash flow compared on the same crore scale.
- Debt
- Free cash flow
- Cash & equivalents
Results
| Metric | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales + | 153 | 182 | 205 | 241 | 225 | 255 | 309 | 312 | 299 | 320 | 320 | 340 | 362 |
| Expenses + | 130 | 155 | 167 | 199 | 191 | 213 | 245 | 252 | 248 | 250 | 248 | 264 | 256 |
| Operating Profit | 23 | 27 | 37 | 42 | 34 | 41 | 63 | 60 | 52 | 70 | 72 | 75 | 106 |
| OPM % | 15% | 15% | 18% | 17% | 15% | 16% | 21% | 19% | 17% | 22% | 22% | 22% | 29% |
| Other Income + | 4 | 33 | 16 | 1 | 12 | 8 | 20 | 23 | 7 | 2 | 58 | 16 | 27 |
| Interest | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Depreciation | 4 | 5 | 8 | 8 | 7 | 7 | 7 | 7 | 8 | 8 | 8 | 9 | 9 |
| Profit before tax | 23 | 54 | 44 | 35 | 38 | 42 | 76 | 75 | 50 | 64 | 121 | 82 | 124 |
| Tax % | 22% | 19% | 30% | 27% | 14% | 24% | 17% | 26% | 25% | 24% | 18% | 26% | 26% |
| Net Profit + | 18 | 44 | 31 | 25 | 33 | 32 | 63 | 55 | 38 | 48 | 100 | 61 | 92 |
| EPS in Rs | 0.39 | 0.98 | 0.69 | 0.56 | 0.73 | 0.71 | 1.39 | 1.22 | 0.83 | 1.06 | 2.20 | 1.34 | 2.03 |
| Raw PDF |
All values in ₹ Crores unless otherwise stated. Source: Screener Master (Standalone).
Events Timeline
Shareholders Annual General Meeting To Be Held On August 27, 2026